Amorphous materials in pharmaceutical formulations yield complex and challenging problems concerning the performance, processing and storage of these products.

The design of accurate and robust analytical methodology is instrumental to developing orally inhaled and nasal drug products (OINDPs) and their appropriate control programmes.

With operating efficiencies increasingly dependent on 'right first time', there is a need to change the status quo in the way processes are controlled.

Rapid advances in drug discovery have led to the identification of a number of compounds with good therapeutic potential.

PAT ensures the continuous control of processes and the timely availability of quality products to market, which results in satisfied customers.